Treatment of advanced (metastatic) NSCLC is currently based on immunotherapy using anti-PD-1 or PD-L1 antibodies, alone or in combination with chemotherapy, but it is accompanied with low response rates and very short median progression-free survival [50]. Here, CD274 is linked to non-small cell lung carcinoma.